Senate Seeks Performance Data From FDA On De Novos, Postmarket Surveillance
This article was originally published in The Gray Sheet
Executive Summary
A Senate panel directs FDA to meets its statutory deadlines for de novo reviews and device risk classifications of devices, and requests data on those programs – as well as for the agency's postmarket device surveillance activities – in a 2017 appropriations bill.